Afatinib improves progression-free survival (PFS) in patients with advanced EGFR-mutant NSCLC compared with chemotherapy as first-line treatment and as second-line treatment after EGFR TKI has an overall response rate (ORR) of approximately 5% to 8% and median PFS (mPFS) of 3.3 to 4.4 months after other EGFR TKI treatment.17, 18, 19. This evidence concerns the gene EGFR and non-small cell lung carcinoma.